Title of article :
Mitochondrial DNA Copy Number Variations and Serum Pepsinogen Levels for Risk Assessment in Gastric Cancer
Author/Authors :
Alikhani ، Mehdi HPGC Research Group, Medical Biotechnology Department - Biotechnology Research Center - Pasteur Institute of Iran , Saberi ، Samaneh HPGC Research Group, Medical Biotechnology Department - Biotechnology Research Center - Pasteur Institute of Iran , Esmaily ، Maryam HPGC Research Group, Medical Biotechnology Department - Biotechnology Research Center - Pasteur Institute of Iran , Michel ، Valérie Unit of Helicobacter Pathogenesis - Institut Pasteur , Tashakoripour ، Mohammad Gastroenterology Department - Amiralam Hospital - Tehran University of Medical Sciences , Abdirad ، Afshin Cancer Institute - Tehran University of Medical Sciences , Aghakhani ، Arezoo Clinical Research Dept. - Pasteur Institute of Iran , Eybpoosh ، Sana Department of Epidemiology and Biostatistics - Research Centre for Emerging and Reemerging Infectious Diseases - Pasteur Institute of Iran , Vosough ، Massoud Department of Regenerative Medicine - Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology - Academic Center for Education, Culture and Research (ACECR) , Mohagheghi ، Mohammad Ali Cancer Research Center - Tehran University of Medical Sciences , Eshagh Hosseini ، Mahmoud Gastroenterology Department - Amiralam Hospital - Tehran University of Medical Sciences , Touati ، Eliette Unit of Helicobacter Pathogenesis - Institut Pasteur , Mohammadi ، Marjan HPGC Research Group, Medical Biotechnology Department - Biotechnology Research Center - Pasteur Institute of Iran
Abstract :
Background: Variations in mtDNA-CN of PBLs, as a potential biomarker for GC screening has currently been subject to controversy. Herein, we have assessed its efficiency in GC screening, in parallel and in combination with sPG I/II ratio, as an established indicator of gastric atrophy. Methods: The study population included GC (n = 53) and non-GC (n = 207) dyspeptic patients. The non-GC group was histologically categorized into CG (n = 104) and NM (n = 103) subgroups. The MtDNA-CN of PBLs was measured by quantitative real-time PCR. The sPG I and II levels and anti-H. pylori serum IgG were measured by ELISA. Results: The mtDNA-CN was found significantly higher in GC vs. non-GC (OR = 3.0; 95% CI = 1.4, 6.4) subjects. Conversely, GC patients had significantly lower sPG I/II ratio than the non-GC (OR = 3.2; CI = 1.4, 7.2) subjects. The combination of these two biomarkers yielded a dramatic amplification of the odds of GC risk in double-positive (high mtDNA-CN-low sPGI/II) subjects, in reference to double-negatives (low mtDNA-CN-high sPGI/II), when assessed against non-GC (OR = 27.1; CI = 5.0, 147.3), CG (OR = 13.1; CI = 2.4, 72.6), or NM (OR = 49.5; CI = 7.9, 311.6) groups. Conclusion: The combination of these two biomarkers, namely mtDNA-CN in PBLs and serum PG I/II ratio, drastically enhanced the efficiency of GC risk assessment, which calls for further validations.
Keywords :
Biomarkers , DNA copy number variation , Mitochondrial DNA , Stomach neoplasmsr
Journal title :
Iranian Biomedical Journal(IBJ)
Journal title :
Iranian Biomedical Journal(IBJ)
